← Eichor
Condition: Other Hematologic Malignant Neoplasms Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Other Hematologic Malignant Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Part
Phase 1 · 42 location(s) · Regeneron Pharmaceuticals · NCT05137054A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Bl
Phase 1 · 21 location(s) · AstraZeneca · NCT07064122Optical Genome Mapping in Hematological Malignancies
Phase N/A · 4 location(s) · University Hospital, Brest · NCT05009537Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments
Phase 1/Phase 2 · 17 location(s) · Bristol-Myers Squibb · NCT05372354A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Le
Phase 2 · 11 location(s) · Curis, Inc. · NCT07271667Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 · 5 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07529782Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Ma
Phase 1 · 17 location(s) · Kyowa Kirin Co., Ltd. · NCT06812104Hairy Cell Leukemia Patient Data Registry
Phase N/A · 8 location(s) · Ohio State University Comprehensive Cancer Center · NCT02560883MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha
Phase 3 · 271 location(s) · Pfizer · NCT06152575Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple
NA · 1 location(s) · Roswell Park Cancer Institute · NCT05312255CIBMTR Research Database
Phase N/A · 2 location(s) · Center for International Blood and Marrow Transplant Researc · NCT01166009Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 · 1 location(s) · Leland Metheny · NCT06680661Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Phase 1/Phase 2 · 18 location(s) · Ascentage Pharma Group Inc. · NCT04494503More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes Aft
NA · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT07705178A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1/Phase 2 · 64 location(s) · AstraZeneca · NCT06564038Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proB
Phase N/A · 1 location(s) · Chinese University of Hong Kong · NCT05797649A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monother
Phase 1/Phase 2 · 36 location(s) · GlaxoSmithKline · NCT05714839Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187Halt Aging in Survivors of Blood Cancers
NA · 1 location(s) · University of Nebraska · NCT07292272A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · 90 location(s) · Pfizer · NCT05020236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.